LAVA Therapeutics’ Nasdaq IPO

NautaDutilh assisted LAVA Therapeutics B.V. on the deal.

LAVA Therapeutics B.V. (Nasdaq: LVTX) closed its IPO on the Nasdaq Global Market, raising approximately USD 100 million in gross proceeds. The Underwriters on this IPO are J.P. Morgan Securities LLC, Jefferies LLC, SVB Leerink LLC and Kempen & Co U.S.A., Inc.

LAVA Therapeutics has its headquarter in Utrecht and was founded in 2016. It is a biotechnology company focused on developing a platform of novel bispecific antibodies engineered to selectively induce gamma-delta T cell-mediated immunity against tumor cells.

The NautaDutilh team was lead by Paul van der Bijl (Picture) and further included Nina Kielman, Dewi Walian, Niek de Kort, Sanne Mesu, Jeroen Boelens, Terrence Dom and Peter Vogels.

Involved fees earner: Jeroen Boelens – NautaDutilh; Niek de Kort – NautaDutilh; Terrence Dom – NautaDutilh; Nina Kielman – NautaDutilh; Sanne Mesu – NautaDutilh; Paul van der Bijl – NautaDutilh; Peter Vogels – NautaDutilh; Dewi Walian – NautaDutilh;

Law Firms: NautaDutilh;

Clients: LAVA Therapeutics;

Print Friendly, PDF & Email
Federica Tiefenthaler

Author: Federica Tiefenthaler